Author: Ken Dropiewski

Cardior Appoints Cardiac Disease and RNA Drug Development Experts to its Scientific Advisory Board Supporting Pipeline Expansion in Both Large and Orphan Cardiac Indications

HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the expansion of its Scientific Advisory Board (SAB) with four newly appointed cardiology and RNA drug development experts. Johann Bauersachs, MD; Perry Elliott, MD; Gerasimos Filippatos, MD, PhD; and Barry […]

Rapid Medical Announces Eitan Havis as International President

Mr. Havis will Lead Commercialization from Europe to Asia YOKNEAM, Israel & MIAMI–(BUSINESS WIRE)–Rapid Medical, a leading developer of neurovascular devices, announces the promotion of Eitan Havis to President, International. Mr. Havis will oversee the commercial expansion of the company’s advanced neurovascular technologies to treat hemorrhagic and ischemic stroke patients in Europe, […]

Avinger Announces Successful Completion of First Cases with the Lightbox 3 Next Generation Imaging Console

REDWOOD CITY, CA / ACCESSWIRE / February 28, 2022 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians in the U.S. have successfully completed first cases with its new […]

HeartFlow Announces CEO Transition

John Farquhar Appointed CEO, John Stevens to Become Vice Chair, Board of Directors MOUNTAIN VIEW, Calif., March 01, 2022 (GLOBE NEWSWIRE) — HeartFlow, Inc., the leader in revolutionizing precision heart care, today announced that John Farquhar has been appointed President and Chief Executive Officer, effective March 1, 2022. Mr. Farquhar has […]

Clinical Study using QuantaFlo® published in Peer-Reviewed Journal of Vascular Surgery

Results show a positive screening of previously undetected PAD was independently associated with short-term and long-term increased risks for mortality and major adverse cardiovascular events SANTA CLARA, Calif., March 1, 2022 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, […]

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

The TicWatch GTH Pro features Arty® Heart Health technology, powered by ATCOR, a subsidiary of CardieX, to monitor arterial and heart health IRVINE, Calif. and SYDNEY, March 1, 2022 /PRNewswire/ — Mobvoi Inc., a leading artificial intelligence-wearable company backed by Google™ and Volkswagen, in partnership with global health tech company CardieX, today announces the launch of […]

Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial

– Adults hospitalized for acute heart failure were 36% more likely to experience a clinical benefit over 90 days if initiated on Jardiance after stabilization and before discharge compared with placebo – The benefit was consistent in adults with new or existing heart failure and in those with either preserved […]

Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Go-to-Market Strategy in U.S. to Optimize Provider Engagement and Drive Demand for VASCEPA® European Expansion Strategy On Track with Reimbursement Negotiations and Launch Preparations for VAZKEPA Underway in Multiple Markets Plans for Regulatory Filings for Approval of VASCEPA in Several Additional Countries in 2022 Company to Host Conference Call Today at […]

BioCardia Receives No Objection Letter from Health Canada, Enabling Company to Expand CardiAMP Cell Therapy Heart Failure Trial into Canada

SUNNYVALE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has received a No Objection Letter from Health Canada, the country’s health services agency, allowing the CardiAMP® Heart Failure Trial to […]